SQZ Biotech completes oversubscribed $72M Series C

posted in: News | 0

SQZ Biotech completes oversubscribed $72M Series C SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced the completion of an oversubscribed $72 million Series C financing. New investors include Everblue, Illumina Ventures, Invus, Orient … Continued

Lilly Completes Acquisition of ARMO BioSciences

posted in: News | 0

Lilly Completes Acquisition of ARMO BioSciences Eli Lilly and Company(NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (NASDAQ: ARMO). Lilly’s tender offer for all outstanding shares of common stock of ARMO, at a price of $50.00 per share … Continued

Organ-Chips Accurately Model and Predict Thrombotic Side Effect Caused by Anti-CD154 Monoclonal Antibody hu5c8; Emulate Publishes Results of Collaborative Research with Janssen

posted in: News | 0

Organ-Chips Accurately Model and Predict Thrombotic Side Effect Caused by Anti-CD154 Monoclonal Antibody hu5c8; Emulate Publishes Results of Collaborative Research with Janssen Emulate, Inc. announced today a published study that demonstrates that its Blood Vessel-Chip accurately modeled and predicted thrombosis, … Continued

Crocus Technology Raises $35M in Financing

posted in: News | 0

Crocus Technology Raises $35M in Financing Crocus Technology, a leading supplier of disruptive Tunnel Magneto-Resistance (TMR) sensors, today announces it has secured $35M in funding through a combination of debt and equity from internal investors and external sources. The funding … Continued

ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

posted in: News | 0

ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a long-acting PEGylated form of recombinant human … Continued

Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma

posted in: News | 0

Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma  Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today … Continued